共 50 条
- [21] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension studyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +Gevaert, PhilippeSaenz, RebeccaCorren, JonathanHan, Joseph K.Mullol, JoaquimLee, Stella E.Ow, Randall A.Zhao, RuiHoward, MonetWong, KitIslam, LutafLigueros-Saylan, MonicaOmachi, Theodore A.Bachert, Claus
- [22] Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritisARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 554 - 562Silverman, ESpiegel, LHawkins, DPetty, RGoldsmith, DSchanberg, LDuffy, CHoward, PStrand, V
- [23] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446Chiorean, MichaelVermeire, SeverinePanes, JulianPeyrin-Biroulet, LaurentZhang, JinkunSands, Bruce E.Lazin, KrisztinaCabell, Chris H.Naik, Snehal U.Klassen, PrestonSandborn, William J.
- [24] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS StudyJOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 950 - 959Vermeire, SeverineChiorean, MichaelPanes, JulianPeyrin-Biroulet, LaurentZhang, JinkunSands, Bruce E.Lazin, KrisztinaKlassen, PrestonNaik, Snehal U.Cabell, Christopher H.Sandborn, William J.
- [25] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension StudyJOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505Baker, MiltonChalabi, YoubGenovese, MarkTaylor, PeterSchlichting, DouglasBeattie, ScottMacias, WilliamKeystone, Edward
- [26] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label StudyJOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937Leonardi, CraigStrober, BruceGottlieb, Alice B.Elewski, Boni E.Ortonne, Jean-Paulvan de Kerkhof, PeterChiou, Chiun-FangDunn, MeleanaJahreis, Angelika
- [27] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)Clinical Rheumatology, 2022, 41 : 1045 - 1055Ruediger B. MuellerHendrik Schulze-KoopsDaniel E. FurstStanley B. CohenKenneth KwokLisy WangTim KilleenJohannes von Kempis
- [28] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055Mueller, Ruediger B.Schulze-Koops, HendrikFurst, Daniel E.Cohen, Stanley B.Kwok, KennethWang, LisyKilleen, Timvon Kempis, Johannes
- [29] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN-LABEL EXTENSION STUDYJCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S85 - S85Genovese, Mark C.Kremer, JoelZhong, ShengFriedman, Alan
- [30] Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Followup StudyARTHRITIS & RHEUMATOLOGY, 2016, 68Brunner, Hermine L.Ruperto, NicolinoQuartier, PierreConstantin, TamasAlexeeva, EkaterinaSchneider, RayfelKone-Paut, IsabelleSchikler, KennethMarzan, KatherineWulffraat, NicoPadeh, ShaiChasnyk, VyacheslavWouters, CarineKuemmerle-Deschner, Jasmin B.Kallinich, TilmannLauwerys, BernardHaddad, ElieNasonov, Evgeny L.Trachana, MariaVougiouka, OlgaLeon, KarolynnSpeziale, AntonioLheritier, KarineVritzali, EleniLovell, Daniel J.Martini, Alberto